Clariant AG (CH:CLN)
:CLN
Want to see CH:CLN full AI Analyst Report?
Top Page
Clariant AG
(CLN)
Select Model
Select Model
Rating:52Neutral
Price Target:
CHF7.50
▼(-9.31% Downside)
Action:Reiterated
Date:06/08/26
The score is primarily held back by weakening financial performance (revenue downtrend, return to net losses, and higher leverage), only partly offset by improved free cash flow. Technicals are also weak with the price below key moving averages and subdued momentum. The dividend yield supports the valuation view, but the negative P/E underscores earnings risk.
Positive Factors
Cash generation
Improved operating cash flow and a meaningful free cash flow uplift in 2025 provide a durable liquidity buffer to support working capital, targeted R&D and maintenance capex, and dividend capacity. Reliable OCF helps absorb cyclical revenue pressure and enables gradual deleveraging despite only moderate conversion.
Negative Factors
Revenue downtrend
A persistent multi-year revenue decline and the return to a net loss in 2025 reduce scale benefits, weaken margin headroom and erode retained earnings. Without a durable reversal in top-line trends, funding for R&D, customer programs and margin recovery is likely to remain constrained over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Improved operating cash flow and a meaningful free cash flow uplift in 2025 provide a durable liquidity buffer to support working capital, targeted R&D and maintenance capex, and dividend capacity. Reliable OCF helps absorb cyclical revenue pressure and enables gradual deleveraging despite only moderate conversion.
Read all positive factors
Clariant AG (CLN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF2.50B
Dividend Yield5.97%
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue Growth-5.71%
EPS Growth-130.75%
CountryCH
Employees10,465
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.23
Shares Outstanding331,939,200
10 Day Avg. Volume1,023,368
30 Day Avg. Volume1,104,585
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.15
Price to Sales (P/S)0.60
P/FCF Ratio9.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF8.36Price Target Upside1.09% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)0.67
Revenue Forecast (FY)CHF3.80B
Clariant AG Business Overview & Revenue Model
Company Description
Clariant AG operates as a global leader in specialty chemicals, organized into three primary business units: Care Chemicals, Catalysis, and Natural Resources. The company develops and supplies a broad spectrum of chemical products and solutions. T...
How the Company Makes Money
Clariant makes money primarily by selling specialty chemical products and related solutions to business customers (B2B) across multiple end markets. Its core revenue model is volume- and value-based sales of formulated products and performance add...
Clariant AG Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 31, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive operational and financial picture: strong margin expansion (EBITDA margin +180 bps), improved absolute EBITDA (+5%), and materially stronger cash conversion (42%, +10 pp) that exceeded medium-term targets. The company also highlighted meaningful sustainability and innovation progress, stronger customer and employee metrics, and tangible savings program delivery (63% of CHF 80m target achieved). Offsetting these positives are soft organic volumes (-1%), segment weaknesses (Adsorbents & Additives decline), working capital build that pressured cash flow timing, legal exposure from an ethylene cartel case (no provisions taken), and continued macroeconomic uncertainty with a cautious 2026 outlook that limits near-term margin upside. Overall, the positives (margin, cash, sustainability, innovation, and savings execution) outweigh the noted challenges, but management remains cautious about near-term market headwinds and segment-specific slowdowns.Positive Updates
Stable Full-Year Sales and Currency Impact
Reported sales for FY2025 were CHF 3.9 billion, flat in local currency. Reported figures were negatively impacted by currency translation of -6% for the year (Q4 experienced a -7% currency headwind).
Negative Updates
Macroeconomic Uncertainty and Slow Industry Growth
Company expects 2026 market growth for Clariant of around 1% and warns of continued macroeconomic challenges: chemicals industry output growth forecast down from 2.9% (2025) to 1.9% (2026), with China slowing significantly and US growth turning negative in forecasts.
Read all updates
Q4-2025 Updates
Positive
Negative
Stable Full-Year Sales and Currency Impact
Reported sales for FY2025 were CHF 3.9 billion, flat in local currency. Reported figures were negatively impacted by currency translation of -6% for the year (Q4 experienced a -7% currency headwind).
Read all positive updates
Company Guidance
Clariant guided that for 2026 it expects a muted macro backdrop (Oxford global GDP 2.8%; chemical output growth easing to 1.9% from 2.9% in 2025; China 2.7% vs 7.4% in 2025; US -0.6% vs +0.6%; Europe +0.5% vs -0.4%), with the company’s addressable market seen growing around 1% and group sales in local currency to be broadly flat (offsetting a c.1% top-line headwind from prior-year portfolio pruning); Care Chemicals underlying is expected to show slight growth, Catalysts to be at levels similar to 2025, and Adsorbents & Additives to face mixed trends. Management expects to further lift EBITDA margin before exceptional items to around 18% (from 17.8% in 2025), deliver most of the remaining CHF 80m performance-improvement program in 2026 (CHF50m or 63% achieved in 2025, CHF19m in Q4, procurement savings CHF22m), manage c.3–4% cost inflation in the year, and continue to target free cash flow conversion of around 40%.Clariant AG Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
48
Neutral
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.92B | 4.15B | 4.38B | 5.20B | 4.37B |
| Gross Profit | 1.22B | 1.26B | 1.20B | 1.02B | 1.29B |
| EBITDA | 650.00M | 696.00M | 510.00M | 337.00M | 723.00M |
| Net Income | -75.00M | 244.00M | 134.00M | -101.00M | 344.00M |
Balance Sheet | |||||
| Total Assets | 5.87B | 6.26B | 5.35B | 6.19B | 7.04B |
| Cash, Cash Equivalents and Short-Term Investments | 617.00M | 471.00M | 593.00M | 758.00M | 476.00M |
| Total Debt | 2.03B | 1.88B | 1.35B | 1.46B | 1.95B |
| Total Liabilities | 3.69B | 3.76B | 3.17B | 3.67B | 4.49B |
| Stockholders Equity | 2.02B | 2.33B | 2.02B | 2.34B | 2.36B |
Cash Flow | |||||
| Free Cash Flow | 234.00M | 209.00M | 214.00M | 290.00M | 3.00M |
| Operating Cash Flow | 379.00M | 418.00M | 421.00M | 502.00M | 363.00M |
| Investing Cash Flow | -309.00M | -805.00M | 45.00M | 140.00M | -143.00M |
| Financing Cash Flow | -28.00M | 277.00M | -356.00M | -652.00M | -538.00M |
Clariant AG Technical Analysis
Positive
8.27
Price Trends
7.54
Positive
7.43
Positive
7.18
Positive
Market Momentum
0.03
Negative
54.12
Neutral
76.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:CLN, the sentiment is Positive. The current price of 8.27 is above the 20-day moving average (MA) of 7.50, above the 50-day MA of 7.54, and above the 200-day MA of 7.18, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.12 is Neutral, neither overbought nor oversold. The STOCH value of 76.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:CLN.
Clariant AG Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | CHF16.62B | 34.78 | 22.08% | 3.16% | -5.85% | 1.24% | |
70 Outperform | CHF30.01B | 27.64 | ― | 2.24% | 0.81% | -1.77% | |
69 Neutral | CHF26.26B | 25.43 | ― | 2.23% | -4.78% | -16.18% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
52 Neutral | CHF2.50B | -32.76 | 5.38% | 5.97% | -5.71% | -130.75% |
* Basic Materials Sector Average
CH:CLN
Clariant AG
7.59
-0.24
-3.09%
CH:GIVN
Givaudan SA
3,252.00
-632.67
-16.29%
CH:SIKA
Sika AG
163.65
-42.66
-20.68%
CH:EMSN
EMS-CHEMIE HOLDING AG
710.50
138.91
24.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.